%0 Journal Article
%A Hütter-Krönke, Marie-Luise
%A Benner, Axel
%A Döhner, Konstanze
%A Krauter, Jürgen
%A Weber, Daniela
%A Moessner, Margit
%A Köhne, Claus-Henning
%A Horst, Heinz A
%A Schmidt-Wolf, Ingo G H
%A Rummel, Mathias
%A Götze, Katharina
%A Koller, Elisabeth
%A Petzer, Andreas L
%A Salwender, Hans
%A Fiedler, Walter
%A Kirchen, Heinz
%A Haase, Detlef
%A Kremers, Stephan
%A Theobald, Matthias
%A Matzdorff, Axel C
%A Ganser, Arnold
%A Döhner, Hartmut
%A Schlenk, Richard F
%T Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
%J Haematologica
%V 101
%N 7
%@ 1592-8721
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2017-04829
%P 839 - 845
%D 2016
%X Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Complete remission or complete remission with incomplete blood count recovery was achieved in 47 (51
%K Aminoglycosides (NLM Chemicals)
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K Cytarabine (NLM Chemicals)
%K Tretinoin (NLM Chemicals)
%K gemtuzumab (NLM Chemicals)
%K Mitoxantrone (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27036160
%2 pmc:PMC5004463
%R 10.3324/haematol.2015.141622
%U https://inrepo02.dkfz.de/record/128816